Address the complexities of malignant and classical hematology development with the expertise, scale and strategic support needed to accelerate programs and bring innovative therapies to patients.
Malignant Hematology trials conducted in the past 5 years
patients enrolled across 32 countries in the past 5 years
Malignant Hematology indications have been supported in the past 5 years, including trials in Multiple Myeloma, Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Overcome the operational and scientific challenges of hematology development with integrated solutions that connect strategy, study design, site activation, trial delivery and evidence generation across the development lifecycle.
Classical Hematology trials conducted in the past 5 years
Patients enrolled across 81 countries in the past 5 years
Indications supported in the past 5 years, including hemophilia, anemias, and immune thrombocytopenic purpura (ITP)
Therapeutically aligned solutions to advance your clinical program to the next milestone.
Access new resources for advanced therapy development, from candidate identification through market authorization.
Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.
The right pediatric program to deliver your medicine sooner.
Unravel the complexities of cancer treatment with patient-level data-driven solutions.
By combining therapeutic expertise, adaptive trial design capabilities, modeling and simulation, regulatory guidance, and global operational support, sponsors canadvance early-phase hematology programs. Our teams work across malignant and classical hematology indications to support first-in-human studies, dose-finding strategies, patient recruitment, and efficient study execution.
Visit our web pages read thelatest oncology insights and learn more about our early phase clinical development expertise.
.svg){kind=icon}
